|
47 Companies |
|
64 Products |
|
64 Products |
|
53 Mechanisms of Action |
|
2 Trials |
|
265 News |
|
| «123456 |
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Mar 30, 2012
P2, N=88, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Recruiting --> Active, not recruiting
- | Trial completion: Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer (clinicaltrials.gov) - Mar 13, 2012
P2, N=44, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 15, 2012
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial: Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (clinicaltrials.gov) - Jan 29, 2012
P2, N=4, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
- Mylotarg (gemtuzumab ozogamicin) / Pfizer
Enrollment change: S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=33, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=55 --> 33
- daunorubicin / Generic mfg.
Enrollment change: S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=71, Completed, Sponsor: Southwest Oncology Group
N=55 --> 33 N=55 --> 71
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=296, Completed, Sponsor: National Cancer Institute (NCI)
N=55 --> 71 Active, not recruiting --> Completed
- daunorubicin / Generic mfg., cyclosporine / Generic mfg.
Trial completion: S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=69, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=33, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- daunorubicin / Generic mfg.
Trial completion: S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=71, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Amdray (valspodar) / Novartis
Trial completion: S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=55, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- daunorubicin / Generic mfg., clofarabine / Generic mfg.
Enrollment change: Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 10, 2012
P2, N=21, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed N=60 --> 21
- Zolinza (vorinostat) / Merck (MSD), Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial termination, Combination therapy: Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 2, 2011
P2, N=107, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
N=60 --> 21 Active, not recruiting --> Terminated
- bortezomib / Generic mfg.
New P2 trial: Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission (clinicaltrials.gov) - Nov 2, 2011
P2, N=35, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Trial completion: Non-Ablative Allo HSCT For Hematologic Malignancies or SAA (clinicaltrials.gov) - Oct 12, 2011
P2, N=58, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- New P2 trial, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 31, 2011
P2, N=42, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Enrollment closed: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 23, 2011
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Biomarker, Adverse events: Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 19, 2011
P=N/A, N=257, Not yet recruiting, Sponsor: Eastern Cooperative Oncology Group
- || Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Enrollment closed: Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=1000, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting